Key facts
- It has raised $9.2M across 1 recorded rounds; the latest was Seed Round ($4.0M) in Sep 2018.
- Notable investors include Gaingels, Metaplanet Holdings, Hemisphere Ventures, Social Capital, Alex Pesch — 42 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 42 names
- ·Watchlist + deal alerts for Ligandal
Funding rounds
1 roundsAbout Ligandal
Developer of nanomedicine therapies designed to offer gene editing tools with non-viral nano-carriers to treat gene-related diseases. The company's therapies include peptide-based technologies for gene therapy, gene editing, regenerative medicine, immunotherapy, advanced antidote-vaccine technology genetic materials and gene-specific payloads with unprecedented precision at the cellular and sub-cellular levels, enabling the medical system to access cell and tissue-specific delivery of gene therapies.
- Industry
- Enterprise Systems (Healthcare)
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2013
- Employees
- 13
- Website
- ligandal.com/
- Ownership
- Privately Held (backing)
Ligandal doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ligandal shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ligandal in its N-PORT filings yet. We sweep new filings monthly.